Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development, Toxicology Research), End-user, By Region, And Segment Forecasts, 2023

The global induced pluripotent stem cells market size is expected to reach USD 3.09 billion by 2030 and is expected to expand at a CAGR of 10.61% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report highlights

By derived cell type, the fibroblasts segment accounted for the largest share of 30.48% in 2022. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
By application, the drug developmentsegment accounted for the largest share of 49.09% in 2022. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.77% in 2022. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
North America held the larger share of 42.36% in 2022. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Product Code: GVR-4-68040-116-1

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. Information analysis
- 1.2.2. Market formulation & data visualization
- 1.2.3. Data validation & publishing
1.3. Research Assumptions
1.4. Information Procurement
- 1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Europe Market: CAGR Calculation
1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
- 3.3.1. Increase in research and development activities in stem cells therapies
- 3.3.2. Surge in adoption of personalized medicine
3.4. Market Restraint Analysis
- 3.4.1. Lack of awareness regarding stem cell therapies
- 3.4.2. High cost of treatment
3.5. Business Environment Analysis
- 3.5.1. PESTEL Analysis
- 3.5.2. Porter's Five Forces Analysis
- 3.5.3. COVID-19 Impact Analysis

Chapter 4. Derived Cell Type Business Analysis

4.1. Global induced pluripotent stem cells market: Derived Cell Type Movement Analysis
4.2. Hepatocytes
- 4.2.1. Hepatocytes Market, 2018 - 2030 (USD Million)
4.3. Fibroblasts
- 4.3.1. Fibroblasts Market, 2018 - 2030 (USD Million)
4.4. Keratinocytes
- 4.4.1. Keratinocytes Market, 2018 - 2030 (USD Million)
4.5. Amniotic Cells
- 4.5.1. Amniotic Cells Market, 2018 - 2030 (USD Million)
4.6. Others
- 4.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

5.1. Global induced pluripotent stem cells market: Application Movement Analysis
5.2. Drug Development
- 5.2.1. Drug Development Market, 2018 - 2030 (USD Million)
5.3. Tissue Engineering & Regenerative Medicine
- 5.3.1. Tissue Engineering & Regenerative Medicine Market, 2018 - 2030 (USD Million)
- 5.3.2. Neurology
  - 5.3.2.1. Neurology Market, 2018 - 2030 (USD Million)
- 5.3.3. Orthopedics
  - 5.3.3.1. Orthopedics Market, 2018 - 2030 (USD Million)
- 5.3.4. Oncology
  - 5.3.4.1. Oncology Market, 2018 - 2030 (USD Million)
- 5.3.5. Cardiovascular and Myocardial Infraction
  - 5.3.5.1. Cardiovascular and Myocardial Infraction Market, 2018 - 2030 (USD Million)
- 5.3.6. Diabetes
  - 5.3.6.1. Diabetes Market, 2018 - 2030 (USD Million)
- 5.3.7. Others
  - 5.3.7.1. Others Market, 2018 - 2030 (USD Million)
5.4. Toxicology Research
- 5.4.1. Toxicology Research Market, 2018 - 2030 (USD Million)
5.5. Disease Modeling
- 5.5.1. Disease Modeling Market, 2018 - 2030 (USD Million)

Chapter 6. End-User Business Analysis

6.1. Global induced pluripotent stem cells market: End-User Movement Analysis
6.2. Academic & Research Institutes
- 6.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
6.3. Pharmaceutical & Biotechnology Companies
- 6.3.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.4. Others
- 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

7.1. Global Induced Pluripotent Stem Cells Market Share By Region, 2022 & 2030
7.2. North America
- 7.2.1. North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. Key Country Dynamics
  - 7.2.2.2. Competitive Scenario
  - 7.2.2.3. Regulatory Framework
  - 7.2.2.4. Target Disease Prevalence
  - 7.2.2.5. U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Key Country Dynamics
  - 7.2.3.2. Competitive Scenario
  - 7.2.3.3. Regulatory Framework
  - 7.2.3.4. Target Disease Prevalence
  - 7.2.3.5. Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Induced Pluripotent Stem Cells Market, 2018 - 2030 (USD Million)
- 7.3.2. Germany
  - 7.3.2.1. Key Country Dynamics
  - 7.3.2.2. Competitive Scenario
  - 7.3.2.3. Regulatory Framework
  - 7.3.2.4. Target Disease Prevalence
  - 7.3.2.5. Germany induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.3.3. UK
  - 7.3.3.1. Key Country Dynamics
  - 7.3.3.2. Competitive Scenario
  - 7.3.3.3. Regulatory Framework
  - 7.3.3.4. Target Disease Prevalence
  - 7.3.3.5. UK induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. Key Country Dynamics
  - 7.3.4.2. Competitive Scenario
  - 7.3.4.3. Regulatory Framework
  - 7.3.4.4. Target Disease Prevalence
  - 7.3.4.5. France induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Key Country Dynamics
  - 7.3.5.2. Competitive Scenario
  - 7.3.5.3. Regulatory Framework
  - 7.3.5.4. Target Disease Prevalence
  - 7.3.5.5. Italy induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Key Country Dynamics
  - 7.3.6.2. Competitive Scenario
  - 7.3.6.3. Regulatory Framework
  - 7.3.6.4. Target Disease Prevalence
  - 7.3.6.5. Spain induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Key Country Dynamics
  - 7.3.7.2. Competitive Scenario
  - 7.3.7.3. Regulatory Framework
  - 7.3.7.4. Target Disease Prevalence
  - 7.3.7.5. Denmark induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Key Country Dynamics
  - 7.3.8.2. Competitive Scenario
  - 7.3.8.3. Regulatory Framework
  - 7.3.8.4. Target Disease Prevalence
  - 7.3.8.5. Sweden induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Key Country Dynamics
  - 7.3.9.2. Competitive Scenario
  - 7.3.9.3. Regulatory Framework
  - 7.3.9.4. Target Disease Prevalence
  - 7.3.9.5. Norway induced pluripotent stem cells market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Target Disease Prevalence
  - 7.4.2.5. Japan induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Target Disease Prevalence
  - 7.4.3.5. China induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Target Disease Prevalence
  - 7.4.4.5. India induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.4.5. South Korea
  - 7.4.5.1. Key Country Dynamics
  - 7.4.5.2. Competitive Scenario
  - 7.4.5.3. Regulatory Framework
  - 7.4.5.4. Target Disease Prevalence
  - 7.4.5.5. South Korea induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.4.6. Australia
  - 7.4.6.1. Key Country Dynamics
  - 7.4.6.2. Competitive Scenario
  - 7.4.6.3. Regulatory Framework
  - 7.4.6.4. Target Disease Prevalence
  - 7.4.6.5. Australia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Key Country Dynamics
  - 7.4.7.2. Competitive Scenario
  - 7.4.7.3. Regulatory Framework
  - 7.4.7.4. Target Disease Prevalence
  - 7.4.7.5. Thailand induced pluripotent stem cells market, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Target Disease Prevalence
  - 7.5.2.5. Brazil induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.5.3. Mexico
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Target Disease Prevalence
  - 7.5.3.5. Mexico induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.5.4. Argentina
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. Target Disease Prevalence
  - 7.5.4.5. Argentina induced pluripotent stem cells market, 2018 - 2030 (USD Million)
7.6. MEA
- 7.6.1. MEA induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Target Disease Prevalence
  - 7.6.2.5. South Africa induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Target Disease Prevalence
  - 7.6.3.5. Saudi Arabia induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Competitive Scenario
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. Target Disease Prevalence
  - 7.6.4.5. UAE induced pluripotent stem cells market, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Competitive Scenario
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Target Disease Prevalence
  - 7.6.5.5. Kuwait induced pluripotent stem cells market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2022
8.4. Company Profiles/Listing
- 8.4.1. STEMCELL Technologies Inc.
  - 8.4.1.1. Overview
  - 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Strategic Initiatives
- 8.4.2. Cellular Engineering Technologies Inc.
  - 8.4.2.1. Overview
  - 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Strategic Initiatives
- 8.4.3. REPROCELL Inc.
  - 8.4.3.1. Overview
  - 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Strategic Initiatives
- 8.4.4. Takara Bio, Inc.
  - 8.4.4.1. Overview
  - 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Strategic Initiatives
- 8.4.5. Axol Bioscience Ltd.
  - 8.4.5.1. Overview
  - 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Strategic Initiatives
- 8.4.6. Fate Therapeutics, Inc.
  - 8.4.6.1. Overview
  - 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Strategic Initiatives
- 8.4.7. FUJIFILM Corporation (FUJIFILM Cellular Dynamics, Inc.)
  - 8.4.7.1. Overview
  - 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Strategic Initiatives
- 8.4.8. Cynata Therapeutics Limited
  - 8.4.8.1. Overview
  - 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Strategic Initiatives
- 8.4.9. Evotec SE
  - 8.4.9.1. Overview
  - 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Strategic Initiatives
- 8.4.10. Astellas Pharma Inc.
  - 8.4.10.1. Overview
  - 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Strategic Initiatives

Product Code: GVR-4-68040-116-1

List of Tables

Table 1 List Of Secondary Sources
Table 2 List Of Abbreviations
Table 3 Global Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 4 Global Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 5 Global Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 6 North America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 7 North America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 8 North America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 9 North America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 10 U.S. Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 11 U.S. Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 12 U.S. Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 13 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 14 Canada Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 15 Canada Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 16 Europe Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 17 Europe Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 18 Europe Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 19 Europe Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 20 UK Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 21 UK Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 22 UK Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 23 Germany Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 24 Germany Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 25 Germany Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 26 France Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 27 France Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 28 France Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 29 Italy Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 30 Italy Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 31 Italy Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 32 Spain Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 33 Spain Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 34 Spain Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 35 Denmark Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 36 Denmark Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 37 Denmark Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 38 Sweden Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 39 Sweden Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 40 Sweden Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 41 Norway Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 42 Norway Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 43 Norway Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 44 Asia Pacific Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 45 Asia Pacific Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 46 Asia Pacific Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 47 Asia Pacific Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 48 China Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 49 China Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 50 China Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 51 Japan Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 52 Japan Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 53 Japan Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 54 India Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 55 India Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 56 India Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 57 South Korea Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 58 South Korea Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 59 South Korea Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 60 Australia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 61 Australia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 62 Australia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 63 Thailand Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 64 Thailand Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 65 Thailand Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 66 Latin America Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 67 Latin America Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 68 Latin America Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 69 Latin America Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 70 Brazil Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 71 Brazil Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 72 Brazil Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 73 Mexico Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 74 Mexico Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 75 Mexico Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 76 Argentina Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 77 Argentina Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 78 Argentina Induced Pluripotent Stem Cells Market by End-User, 2018 - 2030 (USD Million)
Table 79 Middle East & Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa Induced Pluripotent Stem Cells Market by Country, 2018 - 2030 (USD Million)
Table 83 South Africa Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 84 South Africa Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 85 South Africa Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 89 UAE Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 90 UAE Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 91 UAE Induced Pluripotent Stem Cells Market by End-Use, 2018 - 2030 (USD Million)
Table 92 Kuwait Induced Pluripotent Stem Cells Market by Derived Cell Type, 2018 - 2030 (USD Million)
Table 93 Kuwait Induced Pluripotent Stem Cells Market by Application, 2018 - 2030 (USD Million)
Table 94 Kuwait Induced Pluripotent Stem Cells Market By End-Use, 2018 - 2030 (USD Million)
Table 95 Participant's Overview
Table 96 Financial Performance
Table 97 Key Companies Undergoing Expansions
Table 98 Key Companies Undergoing Acquisitions
Table 99 Key Companies Undergoing Collaborations
Table 100 Key Companies Launching New Products/Services
Table 101 Key Companies Undergoing Partnerships
Table 102 Key Companies Undertaking Other Strategies

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market summary, 2022 (USD Million)
Fig. 9 Market segmentation & scope
Fig. 10 Market driver impact
Fig. 11 Market restraint impact
Fig. 12 Penetration & growth prospect mapping
Fig. 13 Porter's analysis
Fig. 14 SWOT analysis
Fig. 15 Global induced pluripotent stem cells market: Derived cell type outlook and key takeaways
Fig. 16 Global induced pluripotent stem cells market: Derived cell type movement analysis
Fig. 17 Global hepatocytes market, 2018 - 2030 (USD Million)
Fig. 18 Global fibroblasts market, 2018 - 2030 (USD Million)
Fig. 19 Global keratinocytes market, 2018 - 2030 (USD Million)
Fig. 20 Global amniotic cells market, 2018 - 2030 (USD Million)
Fig. 21 Global others market, 2018 - 2030 (USD Million)
Fig. 22 Global induced pluripotent stem cells market: Application outlook and key takeaways
Fig. 23 Global induced pluripotent stem cells market: Application movement analysis
Fig. 24 Global drug development market, 2018 - 2030 (USD Million)
Fig. 25 Global tissue engineering & regenerative medicine market, 2018 - 2030 (USD Million)
Fig. 26 Global neurology market, 2018 - 2030 (USD Million)
Fig. 27 Global orthopedics market, 2018 - 2030 (USD Million)
Fig. 28 Global oncology market, 2018 - 2030 (USD Million)
Fig. 29 Global cardiovascular and myocardial infraction market, 2018 - 2030 (USD Million)
Fig. 30 Global diabetes market, 2018 - 2030 (USD Million)
Fig. 31 Global others market, 2018 - 2030 (USD Million)
Fig. 32 Global toxicology research market, 2018 - 2030 (USD Million)
Fig. 33 Global disease modeling market, 2018 - 2030 (USD Million)
Fig. 34 Global induced pluripotent stem cells market: End-use outlook and key takeaways
Fig. 35 Global induced pluripotent stem cells market: End-use movement analysis
Fig. 36 Global academic & research institutes market, 2018 - 2030 (USD Million)
Fig. 37 Global pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
Fig. 38 Global induced pluripotent stem cells market: Regional outlook and key takeaways
Fig. 39 North America induced pluripotent stem cells market, 2018 - 2030 (USD Million)
Fig. 40 U.S. key country dynamics
Fig. 41 U.S. induced pluripotent stem cells market, 2018 - 2030 (USD Million)
Fig. 42 Canada key country dynamics
Fig. 43 Canada induced pluripotent stem cells market, 2018 - 2030 (USD Million)
Fig. 44 Europe induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Germany key country dynamics
Fig. 46 Germany induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 France key country dynamics
Fig. 48 France induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 UK key country dynamics
Fig. 50 UK induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 51 Italy key country dynamics
Fig. 52 Italy induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 53 Spain key country dynamics
Fig. 54 Spain induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 55 Denmark key country dynamics
Fig. 56 Denmark induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 57 Sweden key country dynamics
Fig. 58 Sweden induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 59 Norway key country dynamics
Fig. 60 Norway induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 61 Asia-Pacific induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 62 China key country dynamics
Fig. 63 China induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 64 India key country dynamics
Fig. 65 India induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 66 South Korea key country dynamics
Fig. 67 South Korea induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 68 Japan key country dynamics
Fig. 69 Japan induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 70 Australia key country dynamics
Fig. 71 Australia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 72 Thailand key country dynamics
Fig. 73 Thailand induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 74 Latin America induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 75 Brazil key country dynamics
Fig. 76 Brazil induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 77 Mexico key country dynamics
Fig. 78 Mexico induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 79 Argentina key country dynamics
Fig. 80 Argentina induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 81 MEA induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 82 South Africa key country dynamics
Fig. 83 South Africa induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 84 Saudi Arabia key country dynamics
Fig. 85 Saudi Arabia induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 86 UAE key country dynamics
Fig. 87 UAE induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 88 Kuwait key country dynamics
Fig. 89 Kuwait induced pluripotent stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 90 Market participant categorization
Fig. 91 induced pluripotent stem cells market share analysis, 2022
Fig. 92 Strategy framework

Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development, Toxicology Research), End-user, By Region, And Segment Forecasts, 2023 - 2030

Description

Table of Contents

List of Tables

Induced Pluripotent Stem Cells Market Growth & Trends:

Induced Pluripotent Stem Cells Market Report highlights

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Market Variables, Trends, & Scope

Chapter 4. Derived Cell Type Business Analysis

Chapter 5. Application Business Analysis

Chapter 6. End-User Business Analysis

Chapter 7. Regional Business Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures